Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2017 | Targeting cell cycle checkpoint regulators: ATM and ATR

Melinda L. Telli • 8 Sep 2017
ESMO 2017
General

ATM and ATR have exciting potential as therapeutic targets for the treatment of cancer. In this interview Melinda L. Telli, MD, from Stanford University Medical Center, Stanford, CA, discusses the role of ATM and ATR in the DNA damage response and regulating cell cycle checkpoints, as well as their druggability. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.

More from Melinda L. Telli

4:30
Exciting preliminary results of M6620 combination therapy for triple negative breast cancer
Melinda L. Telli • 8 Sep 2017

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals